

```
BEGIN 5,6,55,154,155,156,312,399,BIOTECH,BIOSCI
>>>      135 is unauthorized
>>>1 of the specified files is not available
      11may05 09:15:42 User208738 Session D1064.1
          $0.80      0.228 DialUnits File1
      $0.80 Estimated cost File1
      $0.10 INTERNET
      $0.90 Estimated cost this search
      $0.90 Estimated total session cost      0.228 DialUnits
```

SYSTEM:OS - DIALOG OneSearch

```
File 5:Biosis Previews(R) 1969-2005/May W1
      (c) 2005 BIOSIS
File 6:NTIS 1964-2005/May W1
      (c) 2005 NTIS, Intl Cpyrght All Rights Res.
File 55:Biosis Previews(R) 1993-2005/May W1
      (c) 2005 BIOSIS
File 154:MEDLINE(R) 1990-2005/May W2
      (c) format only 2005 The Dialog Corp.
File 155:MEDLINE(R) 1951-2005/May W2
      (c) format only 2005 The Dialog Corp.
File 156:ToxFile 1965-2005/May W1
      (c) format only 2005 The Dialog Corporation
*File 156: ToxFile has been reloaded with the 2005 MeSH.
Please see HELP NEWS 156 for details.
File 312:CA SEARCH(R) 1987-1991
      (c) 1997 American Chemical Society
*File 312: Use is subject to the terms of your user/customer agreement.
File 399:CA SEARCH(R) 1967-2005/UD=14220
      (c) 2005 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.
File 8:Ei Compendex(R) 1970-2005/May W1
      (c) 2005 Elsevier Eng. Info. Inc.
File 34:SciSearch(R) Cited Ref Sci 1990-2005/May W1
      (c) 2005 Inst for Sci Info
File 65:Inside Conferences 1993-2005/May W2
      (c) 2005 BLDSC all rts. reserv.
File 71:ELSEVIER BIOBASE 1994-2005/May W1
      (c) 2005 Elsevier Science B.V.
File 73:EMBASE 1974-2005/May W1
      (c) 2005 Elsevier Science B.V.
File 94:JICST-EPlus 1985-2005/Mar W3
      (c)2005 Japan Science and Tech Corp(JST)
File 98:General Sci Abs/Full-Text 1984-2004/Dec
      (c) 2005 The HW Wilson Co.
File 99:Wilson Appl. Sci & Tech Abs 1983-2005/Apr
      (c) 2005 The HW Wilson Co.
File 143:Biol. & Agric. Index 1983-2005/Apr
      (c) 2005 The HW Wilson Co
File 144:Pascal 1973-2005/May W1
      (c) 2005 INIST/CNRS
File 172:EMBASE Alert 2005/May W1
      (c) 2005 Elsevier Science B.V.
File 266:FEDRIP 2005/Jan
      Comp & dist by NTIS, Intl Copyright All Rights Res
File 315:ChemEng & Biotech Abs 1970-2005/Apr
      (c) 2005 DECHEMA
File 357:Derwent Biotech Res. _1982-2005/May W2
      (c) 2005 Thomson Derwent & ISI
```

File 358:Current BioTech Abs 1983-2005/Apr

(c) 2005 DECHEMA

File 369:New Scientist 1994-2005/Apr W1

(c) 2005 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3

(c) 1999 AAAS

***File 370: This file is closed (no updates). Use File 47 for more current information.**

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 1998 Inst for Sci Info

File 35:Dissertation Abs Online 1861-2005/Apr

(c) 2005 ProQuest Info&Learning

File 40:Enviroline(R) 1975-2005/Apr

File 50:CAB Abstracts 1972-2005/Apr

(c) 2005 CAB International

File 91:MANTIS(TM) 1880-2005/Apr

2001 (c) Action Potential

File 110:WasteInfo 1974-2002/Jul

(c) 2002 AEA Techn Env.

***File 110: This file is closed (no updates)**

File 164:Allied & Complementary Medicine 1984-2005/May

(c) 2005 BLHCIS

File 185:Zoological Record Online(R) 1978-2005/May

(c) 2005 BIOSIS

File 391:Beilstein Reactions 2005/Q1

(c) 2005 Beilstein GmbH

File 467:ExtraMED(tm) 2000/Dec

(c) 2001 Informania Ltd.

***File 467: F467 no longer updates; see Help News467.**

7.

Set	Items	Description
---	-----	-----

?

S BACTER? (5N) VACCINE? AND ATTENUAT?

Processed 10 of 35 files ...

Processing

Completed processing all files

6898887 BACTER?

795145 VACCINE?

53638 BACTER? (5N) VACCINE?

949907 ATTENUAT?

S1 4853 BACTER? (5N) VACCINE? AND ATTENUAT?

?

S S1 AND PARTIT? AND (HOK-SOK OR ASD OR SSB OR PHD-DOC OR KIS-KID OR POSTSEGREGAT? O

4853 S1

457404 PARTIT?

0 HOK-SOK

12957 ASD

16541 SSB

2 PHD-DOC

1 KIS-KID

359 POSTSEGREGAT?

1982738 POST

374232 SEGREG?

414 POST(N) SEGREG?

S2 11 S1 AND PARTIT? AND (HOK-SOK OR ASD OR SSB OR PHD-DOC OR
KIS-KID OR POSTSEGREGAT? OR POST (N) SEGREG?)

?

RD S2

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S3 3 RD S2 (unique items)

?

Display 3/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0012342583 BIOSIS NO.: 200000060896

Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA

AUTHOR: Galen James E (Reprint); Nair Jay; Wang Jin Yuang; Wasserman Steven S; Tanner Michael K; Sztein Marcelo B; Levine Myron M

AUTHOR ADDRESS: Center for Vaccine Development, University of Maryland

School of Medicine, 685 W. Baltimore St., Baltimore, MD, USA**USA

JOURNAL: Infection and Immunity 67 (12): p6424-6433 Dec., 1999 1999

MEDIUM: print

ISSN: 0019-9567

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

- end of record -

?

Display 3/3/2 (Item 1 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00319906

IDENTIFYING NO.: 5R01AI040297-08 AGENCY CODE: CRISP

BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA

PRINCIPAL INVESTIGATOR: LEVINE, MYRON M

ADDRESS: MLEVINE@MEDICINE.UMARYLAND.EDU UNIV OF MARYLAND SCH OF MED 685 W BALTIMORE ST, RM 480 BALTIMORE, MD 21201

PERFORMING ORG.: UNIVERSITY OF MARYLAND BALT PROF SCHOOL, BALTIMORE, MARYLAND

SPONSORING ORG.: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

DATES: 2004/01/97 TO 2005/31/05 FY : 2004

- end of record -

?

Display 3/3/3 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0256792 DBR Accession No.: 2000-11282 PATENT

Expression cassette used as live vector vaccine comprises nucleotide sequence encoding origin of replication and plasmid maintenance system which includes a post-segregational killing and a partitioning function - method is useful for gene therapy for disease treatment

AUTHOR: Galen J E

CORPORATE SOURCE: Baltimore, MD, USA.

PATENT ASSIGNEE: Univ.Maryland 2000

PATENT NUMBER: WO 200032047 PATENT DATE: 20000608 WPI ACCESSION NO.:
2000-412091 (2035)
PRIORITY APPLIC. NO.: US 158738 APPLIC. DATE: 19991012
NATIONAL APPLIC. NO.: WO 99US28499 APPLIC. DATE: 19991202
LANGUAGE: English

- end of record -

?

S S1 AND PARTIT?

4853 S1
457404 PARTIT?
S4 12 S1 AND PARTIT?

?

RD S4

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records

S5 4 RD S4 (unique items)

?

Display 5/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:BIOSIS Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0012342583 BIOSIS NO.: 200000060896

Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA

AUTHOR: Galen James E (Reprint); Nair Jay; Wang Jin Yuang; Wasserman Steven S; Tanner Michael K; Sztein Marcelo B; Levine Myron M

AUTHOR ADDRESS: Center for Vaccine Development, University of Maryland School of Medicine, 685 W. Baltimore St., Baltimore, MD, USA**USA

JOURNAL: Infection and Immunity 67 (12): p6424-6433 Dec., 1999 1999

MEDIUM: print

ISSN: 0019-9567

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

- end of record -

?

Display 5/3/2 (Item 1 from file: 98)

DIALOG(R)File 98:General Sci Abs/Full-Text

(c) 2005 The HW Wilson Co. All rts. reserv.

04363650 H.W. WILSON RECORD NUMBER: BGSA00113650 (USE FORMAT 7 FOR FULLTEXT)

Vaccines for mucosal immunity to combat emerging infectious diseases.

van Ginkel, Frederik W

Nguyen, Huan H; McGhee, Jerry R

Emerging Infectious Diseases (Emerging Infect Dis) v. 6 no2 (Mar./Apr. 2000) p. 123-32

SPECIAL FEATURES: bibl il ISSN: 1080-6040

LANGUAGE: English

COUNTRY OF PUBLICATION: United States

WORD COUNT: 5891

- end of record -

?

Display 5/3/3 (Item 1 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00319906

IDENTIFYING NO.: 5R01AI040297-08 AGENCY CODE: CRISP

BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA

PRINCIPAL INVESTIGATOR: LEVINE, MYRON M

ADDRESS: MLEVINE@MEDICINE.UMARYLAND.EDU UNIV OF MARYLAND SCH OF MED 685 W
BALTIMORE ST, RM 480 BALTIMORE, MD 21201

PERFORMING ORG.: UNIVERSITY OF MARYLAND BALT PROF SCHOOL, BALTIMORE,
MARYLAND

SPONSORING ORG.: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

DATES: 2004/01/97 TO 2005/31/05 FY : 2004

- end of record -

?

Display 5/3/4 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0256792 DBR Accession No.: 2000-11282 PATENT

**Expression cassette used as live vector vaccine comprises nucleotide
sequence encoding origin of replication and plasmid maintenance system
which includes a post-segregational killing and a partitioning function
- method is useful for gene therapy for disease treatment**

AUTHOR: Galen J E

CORPORATE SOURCE: Baltimore, MD, USA.

PATENT ASSIGNEE: Univ.Maryland 2000

PATENT NUMBER: WO 200032047 PATENT DATE: 20000608 WPI ACCESSION NO.:
2000-412091 (2035)

PRIORITY APPLIC. NO.: US 158738 APPLIC. DATE: 19991012

NATIONAL APPLIC. NO.: WO 99US28499 APPLIC. DATE: 19991202

LANGUAGE: English

- end of record -

?

?

S S1 AND PARA

4853 S1

334543 PARA

S6 15 S1 AND PARA

?

RD S6

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S7 4 RD S6 (unique items)

?

Display 7/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0012342583 BIOSIS NO.: 200000060896

Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA

AUTHOR: Galen James E (Reprint); Nair Jay; Wang Jin Yuang; Wasserman Steven S; Tanner Michael K; Sztein Marcelo B; Levine Myron M

AUTHOR ADDRESS: Center for Vaccine Development, University of Maryland School of Medicine, 685 W. Baltimore St., Baltimore, MD, USA**USA

JOURNAL: Infection and Immunity 67 (12): p6424-6433 Dec., 1999 1999

MEDIUM: print

ISSN: 0019-9567

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

- end of record -

?

Display 7/3/2 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

09985472 PMID: 1441732

Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen.

Newland J W; Hale T L; Formal S B

Department of Enteric Infections, Walter Reed Army Institute of Research, Washington, DC 20307.

Vaccine (ENGLAND) 1992, 10 (11) p766-76, ISSN 0264-410X

Journal Code: 8406899

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

- end of record -

?

Display 7/3/3 (Item 1 from file: 98)

DIALOG(R)File 98:General Sci Abs/Full-Text

(c) 2005 The HW Wilson Co. All rts. reserv.

04363650 H.W. WILSON RECORD NUMBER: BGSA00113650 (USE FORMAT 7 FOR FULLTEXT)

Vaccines for mucosal immunity to combat emerging infectious diseases.

van Ginkel, Frederik W

Nguyen, Huan H; McGhee, Jerry R

Emerging Infectious Diseases (Emerging Infect Dis) v. 6 no2 (Mar./Apr.

2000) p. 123-32

SPECIAL FEATURES: bibl il ISSN: 1080-6040

LANGUAGE: English

COUNTRY OF PUBLICATION: United States

WORD COUNT: 5891

- end of record -

?

Display 7/3/4 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0293223 DBR Accession No.: 2002-15070 PATENT

Novel vaccine for preventing, treating infectious diseases caused by virus, fungi, protozoa and bacteria, has a carrier strain having membrane vesicle of a microorganism integrated into cell surface of carrier strain - recombinant vaccine and nucleic acid vaccine for use in infection prevention

AUTHOR: KADURUGAMUWA J L; BEVERIDGE T J

PATENT ASSIGNEE: KADURUGAMUWA J L; BEVERIDGE T J 2002

PATENT NUMBER: US 20020028215 PATENT DATE: 20020307 WPI ACCESSION NO.:

2002-315046 (200235)

PRIORITY APPLIC. NO.: US 370860 APPLIC. DATE: 19990809

NATIONAL APPLIC. NO.: US 370860 APPLIC. DATE: 19990809

LANGUAGE: English

- end of record -

?

Display 7/9/2 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

09985472 PMID: 1441732

Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen.

Newland J W; Hale T L; Formal S B

Department of Enteric Infections, Walter Reed Army Institute of Research, Washington, DC 20307.

Vaccine (ENGLAND) 1992, 10 (11) p766-76, ISSN 0264-410X

Journal Code: 8406899

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

-more-

?

Display 7/9/2 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

The construction and characterization of EcSf2a-2, an aroD-deleted Escherichia coli-Shigella hybrid vaccine carrying chromosomal and plasmid genes from Shigella flexneri and expressing S. flexneri 2a somatic antigen in association with E. coli K12 core are described. Expression of hybrid lipopolysaccharide and deletion of aroD resulted in the attenuation of phenotypic characteristics associated with pathogenicity. The addition of an aroD deletion results in a requirement for an aromatic precursor of para-aminobenzoic acid (PABA), an essential bacterial metabolite not present in mammalian tissues. The biosynthesis of hybrid somatic antigen prevents expression of a Sereny-positive reaction by invasive bacteria capable of expressing a plaque-positive phenotype. A functional kcpA gene is required for expression of the plaque-positive phenotype. The presence

of an *aroD* deletion does not interfere with expression of an invasive phenotype; however, in bacteria containing a functional *kcpA* gene, replication and spread by invading bacteria are limited, preventing development of the plaque-positive phenotype.

-more-

?

Display 7/9/2 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

Descriptors: *Escherichia coli--genetics--GE; *Gene Deletion; *Plasmids; *Shigella flexneri--genetics--GE; *Vaccines, Attenuated--genetics--GE; *Vaccines, Synthetic--genetics--GE; Animals; Antibodies, Bacterial--biosynthesis--BI; Antigens, Bacterial--genetics--GE; Escherichia coli--immunology--IM; Escherichia coli--pathogenicity--PY; Genotype; Humans; Immunoglobulin M--biosynthesis--BI; Macaca mulatta; Phenotype; Rabbits; Shigella flexneri--immunology--IM; Shigella flexneri--pathogenicity--PY; Species Specificity; Vaccines, Attenuated--administration and dosage--AD; Vaccines, Attenuated--immunology--IM; Vaccines, Synthetic--administration and dosage--AD; Vaccines, Synthetic--immunology--IM

CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Antigens, Bacterial); 0 (Immunoglobulin M); 0 (Plasmids); 0 (Vaccines, Attenuated); 0 (Vaccines, Synthetic)

Gene Symbol: *aroD*; *ipa*; *kcpA*; *mtl*; *virG*

Record Date Created: 19921201

Record Date Completed: 19921201

- end of record -

?

Ref	Items	Index-term
E1	13	AU=GALEN, J.
E2	6	AU=GALEN, J. E.
E3	13	*AU=GALEN, JAMES
E4	5	AU=GALEN, JAMES E
E5	23	AU=GALEN, JAMES E.
E6	2	AU=GALEN, JAMES EUGENE
E7	2	AU=GALEN, JOSEPH J.
E8	1	AU=GALEN, K. P.
E9	1	AU=GALEN, KAREN
E10	4	AU=GALEN, KAREN P.
E11	1	AU=GALEN, LESLIE BLACKWELL
E12	1	AU=GALEN, LUDWIG A.

Enter P or PAGE for more

?

Ref	Items	Index-term
E1	2	AU=GALEN J.C.
E2	36	AU=GALEN J.E.
E3	12	*AU=GALEN JAMES
E4	70	AU=GALEN JAMES E
E5	24	AU=GALEN JE
E6	7	AU=GALEN K
E7	3	AU=GALEN K D
E8	16	AU=GALEN K P
E9	3	AU=GALEN K.

E10 1 AU=GALEN K.D.
E11 8 AU=GALEN K.P.
E12 5 AU=GALEN KAREN

Enter P or PAGE for more

?

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 100 of 104 returned.**

-
- ☐ 1. [20050063984](#). 06 May 04. 24 Mar 05. Antigenic peptide fragments of vaps protein, and uses thereof. Vanniasinkam, Thiru, et al. 424/190.1; 530/350 A61K039/02 C07K014/195.
-
- ☐ 2. [20050058657](#). 22 Sep 04. 17 Mar 05. Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv. Ertl, Peter Franz, et al. 424/188.1; 424/208.1 424/489 514/44 A61K039/21 A61K039/12 A61K048/00.
-
- ☐ 3. [20050054075](#). 22 Sep 04. 10 Mar 05. Attenuated bacteria useful in vaccines. Turner, Arthur Keith, et al. 435/243; C12N001/00.
-
- ☐ 4. [20050048590](#). 28 Jul 04. 03 Mar 05. Choline binding proteins for anti-pneumococcal vaccines. Masure, H. Robert, et al. 435/7.32; 435/252.3 435/320.1 435/69.3 530/350 536/23.7 C07K014/315 G01N033/554 G01N033/569 C07H021/04 C12N015/74.
-
- ☐ 5. [20050048470](#). 26 Feb 04. 03 Mar 05. Reagents for recombinogenic engineering and uses thereof. Murphy, Kenan C.. 435/5; 435/252.3 435/472 435/69.1 536/23.72 C12Q001/70 C12Q001/68 C07H021/04 C12N009/28 C12N015/74.
-
- ☐ 6. [20050048081](#). 11 Sep 03. 03 Mar 05. Immunogenic compositions comprising DAL/DAT double mutant, auxotrophic attenuated strains of listeria and their methods of use. Frankel, Fred R., et al. 424/199.1; 424/200.1 A61K039/12 A61K039/02.
-
- ☐ 7. [20050048076](#). 01 Dec 95. 03 Mar 05. NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA. APICELLA, MICHAEL A., et al. 424/190.1; A61K039/02.
-
- ☐ 8. [20050042634](#). 12 Apr 04. 24 Feb 05. B. anthracis prevention and treatment: mutant B. anthracis lacking luxS activity and furanone inhibition of growth, AI-2 quorum sensing, and toxin production. Jones, Marcus B., et al. 435/6; 435/252.31 435/320.1 435/69.3 530/350 536/23.7 C07K014/32 C12Q001/68 C07H021/04 C12N009/10 C12N015/74.
-
- ☐ 9. [20050031645](#). 12 Apr 04. 10 Feb 05. Vaccine compositions. Murphy, John R., et al. 424/200.1; 435/252.3 A61K039/12 A61K039/02 C12N001/21.
-
- ☐ 10. [20050019335](#). 27 Sep 04. 27 Jan 05. Salmonella vaccine. Lowery, David E, et al. 424/184.1; A61K039/00 A61K039/38.
-
- ☐ 11. [20050010032](#). 21 May 04. 13 Jan 05. Vaccine for periodontal disease. Hardham, John Morgan, et al. 530/350; C07K017/00 A01N043/04 A61K031/715 C07K001/00 C07K014/00.
-
- ☐ 12. [20050003539](#). 05 Jan 04. 06 Jan 05. Plasmid maintenance system for antigen delivery. Galen, James E.. 435/455; 435/320.1 C12N015/87.
-
- ☐ 13. [20050002946](#). 18 Feb 04. 06 Jan 05. Vaccines and agents for inducing immunity in fish against rickettsial diseases, and associated preventative therapy. Kuzyk, Michael A., et al. 424/184.1; A61K039/00 A61K039/38 A61K039/02.
-

14. [20040260078](#). 22 Mar 04. 23 Dec 04. Novel polynucleotides and polypeptides in pathogenic mycobacteria and their use as diagnostics, vaccines and targets for chemotherapy. Hermon-Taylor, John, et al. 536/23.1; C07H021/02 C07H021/04 C12P021/04.
-
15. [20040258709](#). 15 Jul 04. 23 Dec 04. Hepatitis B virus polypeptides. Chatfield, Steven Neville. 424/186.1; 435/252.3 435/320.1 435/325 435/5 435/69.1 530/350 536/23.72 C12Q001/70 C07H021/04 A61K039/21.
-
16. [20040253710](#). 05 Aug 04. 16 Dec 04. Bacterial vaccine. Turner, Arthur Keith, et al. 435/252.3; A61K039/02 C12N001/20.
-
17. [20040228873](#). 27 Oct 03. 18 Nov 04. Abundant extracellular products and methods for their production and use. Horwitz, Marcus A., et al. 424/190.1; 424/85.2 A61K039/02 A61K038/20.
-
18. [20040223965](#). 04 Feb 03. 11 Nov 04. Hepatitis b core antigen fusion proteins. Gehin, Annick, et al. 424/130.1; A61K039/395.
-
19. [20040209367](#). 20 Jan 04. 21 Oct 04. Mutagenesis technique. Charles, Ian, et al. 435/471; 435/252.3 C12N015/74 C12N001/21.
-
20. [20040161420](#). 05 Jan 04. 19 Aug 04. Plasmid maintenance system for antigen delivery. Galen, James E.. 424/93.21; 435/320.1 435/455 A61K048/00 C12N015/85.
-
21. [20040146486](#). 24 Jan 03. 29 Jul 04. Hybrid vector system for use as a vaccine. Sun, Juan. 424/93.2; 424/199.1 424/200.1 424/85.1 424/85.2 A61K048/00 A61K039/12 A61K039/02.
-
22. [20040137003](#). 12 Jan 04. 15 Jul 04. Regulated antigen delivery system (rads). Curtiss III, Roy. 424/184.1; A61K048/00 A01N063/00 A61K039/00 A61K039/38.
-
23. [20040109875](#). 20 Jan 04. 10 Jun 04. Pro-apoptotic bacterial vaccines to enhance cellular immune responses. Kernodle, Douglas S., et al. 424/200.1; 435/252.3 A61K039/02 C12N001/21.
-
24. [20040101531](#). 15 Apr 03. 27 May 04. Immunogenic compositions and vaccines comprising carrier bacteria that secrete antigens. Curtiss, Roy III, et al. 424/184.1; A61K039/00 A61K039/38.
-
25. [20040086524](#). 30 Sep 02. 06 May 04. Vaccines and agents for inducing immunity in fish against rickettsial diseases, and associated preventative therapy. Kuzyk, Michael A., et al. 424/190.1; 424/234.1 C12Q001/68 A61K039/02.
-
26. [20040054139](#). 11 Mar 03. 18 Mar 04. Modification of hepatitis b core antigen. Page, Mark, et al. 530/350; C07K014/74.
-
27. [20040033234](#). 08 Jul 03. 19 Feb 04. Immunogenic polypeptides encoded by mage minigenes and uses thereof. Berinstein, Neil, et al. 424/185.1; 530/350 A61K039/00 C07K014/74.
-
28. [20040009191](#). 15 Mar 01. 15 Jan 04. SALMONELLA VACCINE MATERIALS AND METHODS. Lowery, David E., et al. 424/200.1; 424/258.1 A61K039/112 A61K039/02.
-
29. [20030236393](#). 24 Mar 03. 25 Dec 03. Virulence genes of *M. marinum* and *M. tuberculosis*. Trucksis, Michele. 536/23.1; C07H021/02 C07H021/04.

-
- ☐ 30. [20030228626](#). 06 Mar 03. 11 Dec 03. Product. Brekke, Ole Henrik, et al. 435/7.1; 435/320.1 435/339 435/340 435/6 435/69.1 530/388.3 530/388.4 536/23.53 C12Q001/68 G01N033/53 C07H021/04 C12P021/02 C12N005/06 C07K016/08 C07K016/12.
-
- ☐ 31. [20030228328](#). 18 Dec 02. 11 Dec 03. Vaccine for periodontal disease. Hardham, John Morgan, et al. 424/190.1; 424/50 435/252.3 435/320.1 435/69.1 530/350 536/23.7 A61K039/02 A61K007/28 C07H021/04 C12P021/02 C12N001/21 C07K014/195.
-
- ☐ 32. [20030224009](#). 09 May 03. 04 Dec 03. Bacterial expression systems. Terry, Tamsin Deborah, et al. 424/184.1; A61K039/00 A61K039/38.
-
- ☐ 33. [20030215464](#). 20 Mar 03. 20 Nov 03. Methods and compositions for vaccination against or involving enterobacteriaceae bacteria. Klimpel, Gary R., et al. 424/200.1; 435/252.3 435/252.33 A61K039/02 C12N001/21.
-
- ☐ 34. [20030185848](#). 15 Dec 00. 02 Oct 03. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia psittaci. Johnston, Stephen A., et al. 424/190.1; 435/252.3 435/320.1 435/69.3 514/44 530/350 536/23.7 A61K039/02 A61K048/00 C07H021/04 C12N001/21 C12N015/74 C07K014/295.
-
- ☐ 35. [20030175293](#). 09 Apr 01. 18 Sep 03. Choline binding proteins for anti-pneumococcal vaccines. Masure, H. Robert, et al. 424/190.1; 424/244.1 514/12 530/350 530/825 930/200 A61K038/00 A61K039/09 C07K014/00 A61K039/02 C07K001/00 C07K017/00.
-
- ☐ 36. [20030170264](#). 03 Apr 03. 11 Sep 03. Stabilisation of plasmid inheritance in bacteria. Turner, Arthur Keith, et al. 424/190.1; A61K039/02.
-
- ☐ 37. [20030165526](#). 30 Sep 02. 04 Sep 03. Vaccines and agents for inducing immunity against rickettsial diseases, and associated preventative therapy. Kuzyk, Michael A., et al. 424/190.1; A61K039/02.
-
- ☐ 38. [20030153527](#). 21 Feb 03. 14 Aug 03. Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same. Powell, Robert J., et al. 514/44; 435/252.3 435/252.33 435/455 A61K048/00 C12N001/21 C12N015/85.
-
- ☐ 39. [20030113845](#). 12 Aug 02. 19 Jun 03. DNA encoding hyaluronan synthase from pasteuria multocida and methods of use. DeAngelis, Paul. 435/69.1; 435/200 435/252.3 435/320.1 435/84 536/23.2 536/53 C12P021/02 C12N001/21 C07H021/04 C08B037/00 C12P019/26 C12N009/24 C12N015/74.
-
- ☐ 40. [20030108562](#). 24 Sep 02. 12 Jun 03. Immune responses to hiv. Hanke, Tomas, et al. 424/188.1; 424/208.1 A61K039/21.
-
- ☐ 41. [20030092087](#). 01 Nov 02. 15 May 03. Ehrlichia disulfide bond formation proteins and uses thereof. Walker, David H., et al. 435/7.32; 435/191 435/252.3 435/320.1 435/69.3 536/23.7 G01N033/554 G01N033/569 C07H021/04 C12P021/02 C12N001/21 C12N015/74 C12N009/06.
-
- ☐ 42. [20030091597](#). 30 Sep 02. 15 May 03. Mycobacterium strains with modified erp gene and vaccine composition containing same. Gicquel, Brigitte, et al. 424/248.1; 435/252.3 435/253.1 A61K039/04 C12N001/21.
-

-
- ☐ 43. [20030031683](#). 03 May 02. 13 Feb 03. Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS positive phenotype. Curtiss, Roy III, et al. 424/200.1; 424/258.1 424/93.2 435/252.3 435/252.8 435/471 435/897 A61K048/00 A01N063/00 A61K039/02 C12N001/20 A61K039/112 C12N015/74 C12N001/00.
-
- ☐ 44. [20030027246](#). 30 Mar 01. 06 Feb 03. Immunogenic peptides derived from prostate-specific membrane antigen (PSMA) and uses thereof. Pedyczak, Artur, et al. 435/69.1; 435/320.1 435/325 435/6 530/328 530/350 536/23.1 C12Q001/68 C07H021/04 C12P021/02 C12N005/06 C07K007/08.
-
- ☐ 45. [20030017168](#). 06 Jun 02. 23 Jan 03. Antigen delivery. Wick, Mary Jo, et al. 424/185.1; A61K039/00.
-
- ☐ 46. [20020183272](#). 17 Dec 01. 05 Dec 02. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia. Johnston, Stephen A., et al. 514/44; 536/23.7 A61K048/00 C07H021/04.
-
- ☐ 47. [20020161192](#). 15 Oct 01. 31 Oct 02. Helicobacter pylori live vaccine. Meyer, Thomas F., et al. 530/350; C07K001/00 C07K014/00 C07K017/00.
-
- ☐ 48. [20020136737](#). 01 May 02. 26 Sep 02. Isolated nucleic acids comprising Listeria dal and dat genes. Frankel, Fred R.. 424/200.1; 435/252.3 A61K039/02 C12N001/21.
-
- ☐ 49. [20020132976](#). 10 Apr 01. 19 Sep 02. Immunogenic peptides derived from prostate-specific antigen (PSA) and uses thereof. Pedyczak, Artur, et al. 530/328; 435/320.1 435/325 435/69.7 530/350 536/23.5 C07H021/04 C12P021/04 C12N005/06 C07K007/06 C07K014/435.
-
- ☐ 50. [20020102722](#). 07 Feb 01. 01 Aug 02. Lac shuttle vectors. Lo, Wei-Yu, et al. 435/320.1; 424/93.21 435/4 A61K048/00 C12Q001/00.
-
- ☐ 51. [20020058041](#). 13 Feb 01. 16 May 02. Kidney-specific tumor vaccine directed against kidney tumor antigen G-250. Beldegrun, Arie, et al. 424/185.1; 435/69.3 530/350 A61K039/00 C07K014/435.
-
- ☐ 52. [20020025939](#). 17 Dec 99. 28 Feb 02. CHORIONIC GONADOTROPIN DNA VACCINES AND METHODS. IVERSEN, PATRICK L.. 514/44; 435/252.33 435/320.1 435/375 435/455 435/91.21 536/23.1 536/23.4 536/23.51 A61K048/00 C07H021/04 C12P019/34 C12N005/08 C12N001/21.
-
- ☐ 53. [20010024653](#). 09 May 01. 27 Sep 01. Attenuated recombinant mycobacteria useful as immunogens or as vaccine components. Gicquel, Bridgitte, et al. 424/200.1; 424/780 435/253.1 435/320.1 536/23.7 A61K039/04 C07H021/04 C12N001/12.
-
- ☐ 54. [6887483](#). 01 Dec 95; 03 May 05. Non-toxic mutants of pathogenic gram-negative bacteria. Apicella; Michael A., et al. 424/256.1; 424/200.1 424/234.1 435/252.3 435/69.3 530/390.1. A61K039102 A61K03902 C12N00120 C07K01600.
-
- ☐ 55. [6872547](#). 11 Oct 00; 29 Mar 05. Functional balanced-lethal host-vector systems. Curtiss, III; Roy. 435/69.1; 424/257.1 424/258.1 435/252.1 435/252.3 435/471. C12P02106 C12N00112 C12N00120 A61K039108 A61K039112.
-
- ☐ 56. [6864365](#). 05 Apr 00; 08 Mar 05. Bacterial fimbrial system for presentation of heterologous peptide sequences. White; Aaron P., et al. 536/23.7; 424/184.1 424/192.1 424/199.1 536/23.1 536/23.4.
-

C07H02104 C07H02100 A61K03900 A61K03912 C12P02108.

57. 6784164. 09 Apr 01; 31 Aug 04. Choline binding proteins for anti-pneumococcal vaccines. Masure; H. Robert, et al. 514/44; 435/252.3 435/254.11 435/320.1 435/6 536/23.72 536/24.32. A61K048/00 C12N001/21 C12N015/31 C12Q001/68.

58. 6780405. 28 Apr 00; 24 Aug 04. Regulated antigen delivery system (RADS). Curtiss, III; Roy, et al. 424/93.1; 424/200.1 424/93.2 424/93.4 435/252.3 435/320.1. A01N063/00 A01N065/00 A61K039/02 C12N001/20 C12N015/00.

59. 6703233. 02 Dec 99; 09 Mar 04. Plasmid maintenance system for antigen delivery. Galen; James E.. 435/252.3; 435/243 435/320.1 435/325 435/69.1 536/23.1 536/24.1. C12N001/21 C12N005/10 C12N015/63 C12N015/68.

60. 6682729. 19 Oct 99; 27 Jan 04. Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same. Powell; Robert J., et al. 424/93.2; 424/184.1 424/93.1 424/93.21 424/93.4 435/320.1 435/325 435/455 435/472 435/480 435/69.1 514/44. A01N063/00 A61K048/00 C12N015/87 C12N015/63 C12N005/00.

61. 6680182. 21 Jul 95; 20 Jan 04. Expression of recombinant fusion proteins in attenuated bacteria. Khan; Mohammed Anjam, et al. 435/69.7; 424/191.1 424/200.1 424/258.1 424/93.2 435/69.3. C12N015/09.

62. 6635749. 01 May 02; 21 Oct 03. Isolated nucleic acids comprising *Listeria* dal and dat genes. Frankel; Fred R.. 536/23.1;. C07H021/04.

63. 6610529. 06 Dec 96; 26 Aug 03. Recombinant bacterial system with environmentally limited viability. Curtiss, III; Roy, et al. 435/252.3; 424/257.1 424/258.1 424/93.1 424/93.2 424/93.48 435/442 435/471 435/481 435/69.1. C12N001/21 A01N063/00 A61K039/108 C12P012/06.

64. 6585976. 10 May 00; 01 Jul 03. Mycobacterium strain with modified ERP gene and vaccine composition containing same. Gicquel; Brigitte, et al. 424/200.1; 424/130.1 424/150.1 424/164.1 424/168.1 424/184.1 424/185.1 424/248.1 424/9.1 424/9.2 530/300 530/350 536/23.1 536/23.7. A61K039/02 A61K039/04 A61K039/38.

65. 6537558. 31 Mar 97; 25 Mar 03. Methods of producing and using virulence attenuated poxR mutant bacteria. Kaniga; Kone. 424/234.1; 424/235.1 424/241.1 424/258.1 435/243 435/252.3. A61K039/02 A61K039/108 A61K039/112 C12N001/00.

66. RE38028. 21 Nov 00; 11 Mar 03. Molecular genetic construction of vaccine strains of pasteurellaceae. Briggs; Robert E., et al. 435/476; 435/243 435/252.1 435/252.3 435/320.1 435/440 435/471 435/477 435/69.1 536/23.1. C12N001/00 C12N001/21 C12N015/00 C12Q001/68.

67. 6504020. 07 Mar 00; 07 Jan 03. Isolated nucleic acids comprising *Listeria* dal and dat genes. Frankel; Fred R., et al. 536/23.1;. C07H021/04.

68. 6500419. 07 Apr 00; 31 Dec 02. Method for introducing and expressing RNA in animal cells. Hone; David M., et al. 424/93.2; 424/93.1 435/252.3 435/320.1 435/455 514/44. A61K048/00 C12N001/21 C12N015/87.

69. 6495661. 21 Jul 98; 17 Dec 02. DNA encoding the outer membrane protein of *Pasteurella*

multocida. Glisson; John Robert, et al. 530/300; 530/317 530/325 530/326 530/350 930/200 930/270. C07K004/00 C07K005/00 C07K007/00 C07K016/00 A61K038/12.

☐ 70. 6488926. 19 Jul 96; 03 Dec 02. Vaccine compositions. Khan; Mohammed Anjam, et al. 424/93.1; 424/184.1 424/193.1 424/197.11 435/252.3 435/320.1 435/325 530/350 530/402 536/23.4. A01N063/00 A61K039/00 C12N015/00 C07H021/04.

☐ 71. 6413768. 02 Dec 98; 02 Jul 02. Expression plasmids. Galen; James E.. 435/320.1; 530/300 530/350 530/403 536/24.1. C12N015/63.

☐ 72. 6383496. 18 May 99; 07 May 02. Recombinant vaccines comprising immunogenic attenuated bacteria having RPOS positive phenotype. Curtiss, III; Roy, et al. 424/200.1; 424/258.1 424/93.2 435/252.3 435/252.8 435/471 435/897. A61K039/02 A61K048/00 C12N015/74 C12N001/21.

☐ 73. 6261568. 11 Jun 98; 17 Jul 01. Attenuated recombinant mycobacteria useful as immunogens or as vaccine components. Gicquel; Brigitte, et al. 424/200.1; 424/248.1 435/253.1 435/6 435/91.1 435/91.2 530/350 536/24.32 536/24.33. A61K039/02 C12Q001/68 C07K001/00 C07H021/04.

☐ 74. 6254874. 13 Apr 95; 03 Jul 01. Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same. Mekalanos; John J., et al. 424/234.1; 424/184.1 424/258.1 424/93.2 424/93.4 424/93.48 435/252.33 435/252.8 435/471 435/69.3. A61K039/00 A61K039/02 A61K039/112 A01N063/00.

☐ 75. 6245335. 01 May 97; 12 Jun 01. Choline binding proteins for anti-pneumococcal vaccines. Masure; H. Robert, et al. 424/190.1; 424/244.1 530/350 530/825. A61K039/09 C07K014/315.

☐ 76. 6221648. 27 Oct 94; 24 Apr 01. Heterologous gene expression in lactococcus, and the expression products therefrom. Le Page; Richard William Falla, et al. 435/252.3; 435/471 435/69.1. C12N015/74 C12N015/09.

☐ 77. 6169175. 06 Aug 97; 02 Jan 01. Preparation and use of recombinant influenza A virus M2 construct vaccines. Frace; A. Michael, et al. 536/23.72; 424/209.1 424/9.34 435/252.33 435/320.1 435/325 435/69.3. C07H021/04 A61K039/145 C12P021/06 C12N001/20.

☐ 78. 6156322. 16 Sep 98; 05 Dec 00. Polynucleotides and polypeptides in pathogenic mycobacteria and their use as diagnostics, vaccines and targets for chemotherapy. Hermon-Taylor; John, et al. 424/248.1; 424/168.1 424/184.1 424/185.1 424/234.1 424/253.1 435/7.1 435/7.2 435/7.32 530/300 530/350. A61K039/04 A61K039/02 A61K039/10 A61K038/00 G01N033/53.

☐ 79. 6150170. 30 Jul 98; 21 Nov 00. Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same. Powell; Robert J., et al. 435/455; 424/184.1 424/93.1 424/93.21 424/93.4 435/320.1 435/472 435/480 435/69.1 514/44. C12N015/63 C12N015/00 C12N005/00 A01N043/04 A61K031/70.

☐ 80. 6130082. 14 Feb 92; 10 Oct 00. Recombinant flagellin vaccines. Majarian; William R., et al. 435/252.3; 424/192.1 424/200.1 424/258.1 424/93.2 435/252.33 435/320.1 536/23.4 536/23.7. C12N001/21 C12N015/62 C12N015/00 A61K039/116.

☐ 81. 6099848. 18 Nov 97; 08 Aug 00. Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use. Frankel; Fred R., et al. 424/246.1; 424/200.1 424/234.1 424/93.46 435/71.2. A61K039/07.

-
- ☐ 82. 6033877. 31 Oct 96; 07 Mar 00. Peptide expression and delivery system. Murphy; Timothy F., et al. 435/69.7; 435/252.3 435/320.1 530/350 536/23.4. C12N015/31 C12N015/62 C12N015/63 C12N015/74.
-
- ☐ 83. 5981229. 10 Apr 96; 09 Nov 99. Bacterial exported proteins and acellular vaccines based thereon. Masure; H. Robert, et al. 435/69.3; 435/252.3 435/254.11 435/320.1 435/69.1 536/23.1 536/23.7. C12N015/31 C12N015/74 C12N015/70 C12N015/81 C07H021/04.
-
- ☐ 84. 5965139. 16 Apr 98; 12 Oct 99. Chicken infectious anemia virus vaccine. Schat; Karel A., et al. 424/199.1; 424/185.1 424/186.1 424/192.1 424/193.1 424/196.11 424/202.1 424/204.1 424/214.1 424/229.1 424/278.1 424/816 435/235.1 435/252.3 435/254.11 435/320.1 435/69.1 435/69.3 536/23.72. A61K039/12 C12N015/34 C12N007/01 C12N005/10.
-
- ☐ 85. 5961983. 24 May 95; 05 Oct 99. Stable pura vectors and uses therefor. Brey; Robert N., et al. 424/200.1; 424/234.1 424/257.1 424/258.1 424/272.1 435/320.1 435/69.3 536/23.5 536/23.7. A61K039/02 C12N015/11 C12N015/63.
-
- ☐ 86. 5928900. 18 May 94; 27 Jul 99. Bacterial exported proteins and acellular vaccines based thereon. Masure; H. Robert, et al. 435/69.3; 424/185.1 424/190.1 424/244.1 530/350. C12P021/06 A61K039/00 A61K039/02 C07K001/00.
-
- ☐ 87. 5919663. 30 Jan 95; 06 Jul 99. Stable purA vectors and uses therefor. Brey; Robert N., et al. 435/69.3; 435/252.3 435/252.33 435/320.1 435/6 536/23.1. C12P021/02 C12N015/63 C12N001/21 C07H021/04.
-
- ☐ 88. 5877159. 03 May 95; 02 Mar 99. Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same. Powell; Robert J., et al. 514/44; 424/184.1 424/93.1 424/93.21 424/93.4 435/235.1 435/320.1 435/472 435/480 435/69.1 536/24.1. A01N043/04 A61K031/70 C12N015/63.
-
- ☐ 89. 5843711. 02 Nov 95; 01 Dec 98. Diphtheria toxin receptor-binding region. Collier; R. John, et al. 435/69.1; 435/252.3 435/320.1 435/69.3 514/2 536/22.1 536/23.1 536/23.2 536/23.4 536/23.7. C12N015/00.
-
- ☐ 90. 5840556. 19 Dec 96; 24 Nov 98. Molecular genetic construction of vaccine strains of pasteurellaceae. Briggs; Robert E., et al. 435/473; 435/243 435/252.1 435/252.3 435/320.1 435/476 435/6 435/69.1 536/23.1. C12N001/00 C12N001/21 C12N015/00 C12Q001/68.
-
- ☐ 91. 5840483. 07 Jun 95; 24 Nov 98. Method of maintaining a desired recombinant gene in a genetic population of cells. Curtiss, III; Roy. 435/6; 435/252.3 435/252.33 435/320.1. C12Q001/68.
-
- ☐ 92. 5824538. 06 Sep 95; 20 Oct 98. Shigella vector for delivering DNA to a mammalian cell. Branstrom; Arthur A., et al. 435/252.1; 424/93.2 435/245 435/252.3 435/455 435/822. C12N001/00 C12N001/20 C12N015/00.
-
- ☐ 93. 5789567. 03 Jul 95; 04 Aug 98. Chicken infectious anemia virus vaccine. Schat; Karel A., et al. 435/325; 424/199.1 424/204.1 424/93.2 435/235.1 435/320.1 435/69.3 536/23.1. C07H021/04 C12P021/02.
-
- ☐ 94. 5703219. 22 May 95; 30 Dec 97. Nucleic acid encoding helicobacter pylori enolase.
-

Thompson; Stuart A., et al. 536/23.2; 435/252.3 435/320.1. C07H021/04 C12N015/63 C12N001/21.

☐ 95. 5691449. 25 May 95; 25 Nov 97. Respiratory syncytial virus vaccines. Paradiso; Peter R., et al. 530/350; 424/211.1 530/395. C07K001/00 C07K014/00 C07K017/00 A61K039/155.

☐ 96. 5683700. 06 Jun 95; 04 Nov 97. Expression of recombinant proteins in attenuated bacteria. Charles; Ian George, et al. 424/200.1; 424/93.2 435/252.3 435/252.8. A61K039/00.

☐ 97. 5672345. 10 Mar 95; 30 Sep 97. Selective maintenance of a recombinant gene in a population of vaccine cells. Curtiss, III; Roy. 424/93.2; 435/252.3 435/69.1 435/71.2. A61K039/02 C12P021/00 C12N015/00 C12N001/21.

☐ 98. 5639853. 20 Sep 89; 17 Jun 97. Respiratory syncytial virus vaccines. Paradiso; Peter R., et al. 530/324; 424/211.1 530/350. C07K001/00 C07K005/00 A61K038/00 A61K039/155.

☐ 99. 5547664. 12 Dec 94; 20 Aug 96. Expression of recombinant proteins in attenuated bacteria. Charles; Ian G., et al. 424/93.2; 424/93.4 424/93.48 435/252.3 435/252.8. A61K039/08 A61K039/10 A61K039/112 C12N001/21.

☐ 100. 5434253. 21 Mar 94; 18 Jul 95. DNA encoding Helicobacter pylori recombinase. Thompson; Stuart A., et al. 536/23.2; 435/252.1 435/252.3 435/822. C07H021/04.

Generate Collection

Print

Terms	Documents
L1 and origin near3 replicat\$	104

[Prev Page](#) [Next Page](#) [Go to Doc#](#)